Research Article

Thromboembolic Events Secondary to Endoscopic Cyanoacrylate Injection: Can We Foresee Any Red Flags?

Table 2

Postoperative events including subsequent severe adverse event (SAE), patient outcome, and probable cause.

PatientPostoperative
drug use
Adverse eventTreatmentHospital stayOutcomeProbable cause

(1)NoneAcute pulmonary embolismBCLS1 dayDeathLarge spontaneous gastrorenal and splenorenal shunt

(2)Carbazochrome 80 mg
Vitamin K1 10 mg
Somatostatin 6 mg
Acute splenic infarctionDalteparin 5000 IU
Antibiotics (meropenem + vancomycin)
64 daysSurvivalRegurgitation of tissue adhesive through the portovenous system or probable AVM

(3)Carbazochrome 80 mg
Somatostatin 3 mg
Hemocoagulase 2 U
Acute cerebral infarctionDalteparin 5000 IU
Edaravone
Mannitol
Dexamethasone
13 daysSurvivalSpontaneous portorenal shunt

(4)Hemocoagulase 1 IU
Somatostatin 6 mg
Acute superior mesenteric infarctionLMWH 4000 IU
Simethicone p.o.
9 daysDeathRegurgitation of tissue adhesive through the portovenous system or probable AVM

(5)Hemocoagulase 1 IU
Somatostatin 6 mg
Acute cerebral infarctionLMWH 4000 IU
Citicoline
GM-1
Dexamethasone
42 daysSurvivalSpontaneous portoazygous shunt